Financials
- Market Capitalization 157.63 M
- Employee 184
- Founded 2004
- CEO Laura Niklason
- Website www.humacyte.com
- Headquarter Delaware, United States
- FIGI BBG00XPPT7S7
- Industry Biotechnology
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 3766 | MOLN Molecular Partners AG - American Depositary Shares | 4.00 USD | -0.25% | 0.00% | +3.90% | +10.50% | 161.50 M USD | ||
| 3776 | ADCT ADC Therapeutics SA Common Shares | 1.24 USD | -0.80% | -8.15% | +15.89% | -61.37% | 157.72 M USD | ||
| 3782 | NRXP NRX Pharmaceuticals, Inc. - Common Stock | 4.33 USD | +4.34% | +5.61% | +6.13% | +143.26% | 156.87 M USD | ||
| 3792 | LENZ LENZ Therapeutics, Inc. - Common Stock | 4.93 USD | -5.74% | -13.96% | -25.19% | -84.83% | 154.58 M USD |
Frequently asked questions about Humacyte, Inc. - Common Stock
What is the Humacyte, Inc. - Common Stock stock price today?
The current price of Humacyte, Inc. - Common Stock (HUMA) is 0.71. Over the past 24 hours, the stock has changed by +2.90%. Follow the HUMA chart for real-time price dynamics.
What is the stock ticker of Humacyte, Inc. - Common Stock?
Humacyte, Inc. - Common Stock trades under the ticker HUMA. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is Humacyte, Inc. - Common Stock stock going up?
HUMA has changed by -5.33% over the last week, -33.64% over the last month, and -69.53% over the last year. Review the chart to see whether the current move is part of a broader trend.
What was Humacyte, Inc. - Common Stock net income for the last quarter?
Humacyte, Inc. - Common Stock reported net income of -17.62 M for the last quarter. The previous quarter showed -24.8 M, which means net income changed by +28.97%.
How many employees does Humacyte, Inc. - Common Stock have?
As of the latest available data, Humacyte, Inc. - Common Stock has 184 employees. Workforce size can provide additional context about the company's scale and operations.
What is Humacyte, Inc. - Common Stock EBITDA?
Humacyte, Inc. - Common Stock EBITDA is -26.86 M, and its EBITDA margin is -5 426.87%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.
How can I buy Humacyte, Inc. - Common Stock stock?
You can buy Humacyte, Inc. - Common Stock (HUMA) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in Humacyte, Inc. - Common Stock stock?
Investing in Humacyte, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the HUMA chart and related analysis on metatrader.com as part of your research.